GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.

GSK's head of respiratory and immunology R&D, Kaivan Khavandi, said that the drug had achieved the "fundamental treatment goal in asthma" by slashing asthma attacks and hospitalisations.

This Fool wants to make the most of the benefits a Stocks and Shares ISA provides. He's keen on these two stocks. The post I ...

r&d GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information.

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

Two specialists are impressed by the preliminary findings of a randomized trial in newly diagnosed patients, but another is ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...